Total Payments
$196,454
2024 Payments
$7,434
Companies
28
Transactions
550
Medicare Patients
7,072
Medicare Billing
$1.1M
Payment Breakdown by Category
Other$115,570 (58.8%)
Consulting$52,206 (26.6%)
Food & Beverage$17,216 (8.8%)
Travel$11,356 (5.8%)
Education$106.02 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $112,548 | 49 | 57.3% |
| Consulting Fee | $52,206 | 58 | 26.6% |
| Food and Beverage | $17,216 | 404 | 8.8% |
| Travel and Lodging | $11,356 | 30 | 5.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,500 | 3 | 0.8% |
| Grant | $1,222 | 1 | 0.6% |
| Honoraria | $300.00 | 2 | 0.2% |
| Education | $106.02 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $127,473 | 169 | $0 (2024) |
| Abbott Laboratories | $49,930 | 246 | $0 (2024) |
| Kestra Medical Technology Services, Inc. | $6,557 | 7 | $0 (2024) |
| Edwards Lifesciences Corporation | $4,312 | 7 | $0 (2023) |
| Boston Scientific Corporation | $1,266 | 2 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $1,121 | 4 | $0 (2021) |
| Akcea Therapeutics, Inc. | $690.23 | 12 | $0 (2021) |
| Alnylam Pharmaceuticals Inc. | $627.49 | 28 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $606.98 | 3 | $0 (2024) |
| Covidien LP | $466.00 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,434 | 32 | Kestra Medical Technology Services, Inc. ($6,343) |
| 2023 | $6,049 | 44 | Edwards Lifesciences Corporation ($4,132) |
| 2022 | $5,080 | 31 | Abbott Laboratories ($4,265) |
| 2021 | $7,196 | 69 | Abbott Laboratories ($5,173) |
| 2020 | $8,071 | 67 | Abbott Laboratories ($5,956) |
| 2019 | $49,079 | 78 | Novartis Pharmaceuticals Corporation ($42,801) |
| 2018 | $68,584 | 110 | Novartis Pharmaceuticals Corporation ($52,784) |
| 2017 | $44,963 | 119 | Novartis Pharmaceuticals Corporation ($29,322) |
All Payment Transactions
550 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: Genetic Disease | ||||||
| 12/05/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: Heart Failure | ||||||
| 11/22/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| Category: Cardiology | ||||||
| 11/22/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Cardiology | ||||||
| 11/15/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: Heart Failure | ||||||
| 10/21/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $26.43 | General |
| Category: Heart Failure | ||||||
| 10/21/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Heart Failure | ||||||
| 10/01/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Cardiology | ||||||
| 09/27/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $22.01 | General |
| Category: Genetic Disease | ||||||
| 09/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: Cardio-pulmonary | ||||||
| 09/16/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: Heart Failure | ||||||
| 09/12/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: Cardiology | ||||||
| 08/27/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: Heart Failure | ||||||
| 08/12/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Heart Failure | ||||||
| 07/05/2024 | Abbott Laboratories | OPTIS (Device) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: Vascular | ||||||
| 05/29/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $26.82 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 05/29/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: Genetic Disease | ||||||
| 05/28/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: Heart Failure | ||||||
| 05/13/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: Heart Failure | ||||||
| 05/08/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $43.15 | General |
| Category: Cardiology | ||||||
| 05/07/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $28.10 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 04/11/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: Genetic Disease | ||||||
| 04/03/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: Heart Failure | ||||||
| 03/26/2024 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $7.46 | General |
| Category: Heart Failure | ||||||
| 03/07/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: Genetic Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,684 | 3,580 | $764,709 | $203,802 |
| 2022 | 14 | 2,142 | 4,544 | $1.3M | $344,370 |
| 2021 | 15 | 1,979 | 3,993 | $1.1M | $302,307 |
| 2020 | 12 | 1,267 | 3,018 | $797,068 | $208,563 |
Total Patients
7,072
Total Services
15,135
Medicare Billing
$1.1M
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 161 | 537 | $144,990 | $39,362 | 27.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 257 | 292 | $130,409 | $35,508 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 293 | 400 | $132,800 | $34,391 | 25.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 260 | 669 | $115,737 | $31,413 | 27.1% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Facility | 2023 | 125 | 571 | $50,248 | $13,721 | 27.3% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 121 | 602 | $52,976 | $13,025 | 24.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 70 | 74 | $35,594 | $9,478 | 26.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 53 | 54 | $31,914 | $8,583 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 101 | 108 | $24,408 | $6,239 | 25.6% |
| 33289 | Insertion of wireless pressure sensor into lung artery through tube with review by radiologist | Facility | 2023 | 13 | 13 | $15,912 | $4,180 | 26.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 27 | $10,962 | $3,002 | 27.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 11 | 11 | $6,853 | $1,730 | 25.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 168 | 183 | $5,124 | $1,316 | 25.7% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 11 | 11 | $3,201 | $874.72 | 27.3% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2023 | 11 | 11 | $2,816 | $771.21 | 27.4% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 17 | 17 | $765.00 | $209.61 | 27.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 431 | 1,364 | $334,180 | $91,508 | 27.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 374 | 412 | $280,572 | $75,652 | 27.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 150 | 509 | $178,659 | $48,917 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 367 | 531 | $178,947 | $46,508 | 26.0% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2022 | 176 | 972 | $89,424 | $23,449 | 26.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 139 | 152 | $71,288 | $19,448 | 27.3% |
| 33289 | Insertion of wireless pressure sensor into lung artery through tube with review by radiologist | Facility | 2022 | 37 | 37 | $48,507 | $13,381 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 56 | 59 | $29,854 | $8,026 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 103 | 120 | $27,960 | $7,153 | 25.6% |
About Dr. Rita Jermyn, MD
Dr. Rita Jermyn, MD is a Internal Medicine healthcare provider based in Roslyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2008. The National Provider Identifier (NPI) number assigned to this provider is 1811140627.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rita Jermyn, MD has received a total of $196,454 in payments from pharmaceutical and medical device companies, with $7,434 received in 2024. These payments were reported across 550 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($112,548).
As a Medicare-enrolled provider, Jermyn has provided services to 7,072 Medicare beneficiaries, totaling 15,135 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Advanced Heart Failure and Transplant Cardiology, Cardiovascular Disease
- Location Roslyn, NY
- Active Since 10/24/2008
- Last Updated 09/02/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1811140627
Products in Payments
- ENTRESTO (Drug) $127,452
- CardioMEMS HF System (Device) $42,100
- Assure WCD (Device) $6,557
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $2,918
- CARDIOMEMS (Device) $2,294
- GENERAL TACHY (Device) $1,222
- FARXIGA (Drug) $1,101
- HeartMate 3 Left Ventricular Assist Device (Device) $850.59
- TEGSEDI (Drug) $840.23
- Circulatory Support (Device) $547.44
- LifeVest (Device) $462.10
- Veltassa (Drug) $407.44
- Adempas (Drug) $400.00
- JARDIANCE (Drug) $385.60
- AMVUTTRA (Drug) $330.03
- ONPATTRO (Drug) $297.46
- HeartMate 3 Left Ventricular Dev (Device) $277.20
- XARELTO (Drug) $250.00
- Verquvo (Drug) $206.98
- HeartMate (Device) $200.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Roslyn
Joshua Stern, M.d, M.D
Internal Medicine — Payments: $116,680
Internal Medicine $116,680
Dr. Xiao Li Ren, M.d, M.D
Internal Medicine — Payments: $4,848
Internal Medicine $4,848
Ryan Murphy, D.o, D.O
Internal Medicine — Payments: $3,485
Internal Medicine $3,485
Natalia Hochbaum, M.d, M.D
Internal Medicine — Payments: $3,414
Internal Medicine $3,414
Dr. Stephen Mezzafonte, M.d, M.D
Internal Medicine — Payments: $2,725
Internal Medicine $2,725
Viren Amin, M.d, M.D
Internal Medicine — Payments: $2,422
Internal Medicine $2,422